Medicinal chemistry: designed compounds and measured tradeoffs
Which new design approaches connect chemical changes with measured activity and developability?
Five specialists select new research papers. Rowan separately reports important news across the field. Each topic can include up to five significant papers per day, and the news digest up to five significant stories.
We publish when there is something worth reading. Dates show when each update was prepared. Our weekly editions bring the deeper reporting and analysis.
Which new design approaches connect chemical changes with measured activity and developability?
Five papers examine model comparisons, macrocycle permeability, metal docking and ambiguous affinity traces.
Five developments link AI tools to funded programmes, experimental feedback and scientific strategy.
Five studies connect computational predictions with assay workflows and preclinical pharmacology.
Five papers connect synthesis decisions, catalytic prediction and numerical accountability.
Which new datasets, controlled comparisons and physical models improve decisions in materials simulation?
Which chemical changes improve target engagement, resistance reversal and exposure?
Five studies test molecular identity, antigen recognition and transferable binding predictions.
Funding announcements and research programmes connect AI models to experimental development.
Five studies examine drug-response prediction, metabolic sites, tracer distribution and animal pharmacology.
Which new studies improve physical sample handling, failure diagnosis, reaction modelling and adaptable flow chemistry?
Which new measurements and benchmarks clarify how materials models transfer, extrapolate and enter simulation workflows?
How do INCB127443, DF142, an allosteric SHP2 scaffold, spirocyclic FAPI tracers and a BET series connect chemical substitutions to target engagement and biological performance?
How do new molecular-discovery studies test small structural changes, generated interfaces and structural prediction errors?
Five developments connect AI discovery to clinical finance, industrial evidence and open modelling workflows.
Five studies examine pharmacological predictions against external data, animal experiments and alternative models.
Which new computational tools connect synthesis decisions to checked routes, measured chemistry and analytical performance?
Which new material-design and simulation methods connect learning with physical observables?
Which modelling studies offer useful selectivity and lead-design hypotheses, and what do they establish?
How do new molecular methods connect predictions to experiments and expose hidden evaluation assumptions?
A verified-access beta and an integrated dose-prediction product change research workflows.
Two studies connect AI-assisted pharmacological hypotheses to experimental or external-data checks.
Which new benchmarks and data workflows make computational chemistry more useful for experimental decisions?
Which new materials studies establish useful structure, stability and model-validation evidence?
Which measured optimisation results and comparative checks improve medicinal-chemistry decisions?
Which new molecular tools improve usable evidence, and where do benchmark definitions constrain their claims?
Five developments in toxicity data, clinical formulation, trial evidence and research infrastructure.
Four papers on validation, safety signals, functional drug effects and antimicrobial predictions.
What do new experiments and comparative tests establish about automated chemistry and biosynthetic prediction?
Five studies examine catalyst structures, efficient derivatives, physically checked models and evidence-linked diffraction records.